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ABSTRACT 
The deep-sea habitat is a source of very potent marine-derived agents that may inhibit the growth of human can-
cer cells “in vitro” and “in vivo”. Salinosporamide-A, Marizomib, by Salinispora species is a proteasome inhibi-
tor with promising anticancer activity (Phase I/II trials). Different deep-sea-derived drugs are under preclinical 
evaluation. Cancer is a complex disease that may be represented by network medicine. A simple consequence is 
the change of the concept of target entity from a single protein to a whole molecular pathway and or cellular 
network. Deep-sea-derived drugs fit well to this new concept. 
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INTRODUCTION 
“Consider the subtleness of the sea; how 
its most dreaded creatures glide under water, 
unapparent for the most part, and treacherously 
hidden beneath the loveliest tints of azure. Con-
sider also the devilish brilliance and beauty of 
many of its most remorseless tribes, as the dain-
ty embellished shape of many species of sharks. 
Consider, once more, the universal cannibalism 
of the sea; all whose creatures prey upon each 
other, carrying on eternal war since the world 
began.” 
 
Herman Melville, Moby Dick. 
 
The ocean explorations start since 4500 
BC when people of Mesopotamia, Greece 
and China began to dive into the sea to col-
lect food, make commerce (i.e. pearl-diving 
industry) and possibly war 
[http://www.seagrant.wisc.edu/madisonjason
11/timeline/index_4500BC.html]. The first 
testimony of marine medicine comes from 
2953 BC during emperor Fu His in China as 
a tax for profits of fish-derived medicine (Jia 
et al., 2004). A Greeks epigraphy at the 
Sanctuary of “Asklepios” at Epidaurus (4th 
century BC) refers to a missed sponge fisher-
men (Guarducci, 1995). Thus, on 400 BC 
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Hippocrates reported that sea sponges has 
antibiotic effects and recommended to put 
them on soldiers’ wounds (Riddle, 1987). 
Now, it has been shown that sponges pro-
duce bioactive secondary metabolites (SMs), 
that origin directly by sponges or indirectly 
by their associated microorganisms, that 
could work to fight infections (Laport et al., 
2009). Currently, technological innovations 
in underwater vehicles such as submersibles, 
ROVs (Remotely Operated Vehicles), and 
AUVs (Autonomous Underwater Vehicles) 
allow the exploration of the depths of the 
ocean and in turn allow the discovery of 
novel marine species potentially useful in 
medicine. The “ocean” [from Ancient Greek 
Ὠκεανός (Okeanos)] occupies two-thirds of 
planet's surface. It is divided in 4 ocean 
zones (from shoreline to open ocean): (1) the 
Intertidal Zone, (2) the Neritic Zone, (3) the 
Oceanic Zone, and (4) the Benthic Zone that 
underlies all the other zones. Technically, the 
deep sea is located below a depth of 200 me-
ters, further divided into deep sea zones. As 
a consequence of thermal or pressure inter-
faces each zone has characteristic life and 
conditions. The deep-water ecologist Koslow 
defines the deep sea “as the area below 
which photosynthesis can function” (Koslow, 
2007). Two zones are biologically interesting 
such as: (1) the mesopelagic zone, the “Twi-
light Zone” (between 200 meters to 700 or 
1000 meters down), where, depending on 
water clarity (transparency or clearness), 
photosynthesis can take place; and (2) the 
boundary between the mesopelagic and the 
bathypelagic zone that contains the deep 
scattering layer – a layer of fish, squid, crus-
taceans etc, that migrate each day from the 
deep ocean to the shallows at night (Koslow, 
2007). In this review, we exemplify current 
deep sea (below 200 meters equivalent to 
656 feet) drug discovery, and development 
of products as anticancer agents with specific 
examples. Drugs derived by organisms that 
live upper 200 meters, such as AplidinTM 
(PharmaMar USA Inc.) by Aplidium albi-
cans or YondelisTM (Formerly ET-743, 
PharmaMar in partnership with Johnson & 
Johnson Pharmaceutical Research & Devel-
opment, L.C.C. -J&JPRD-) by Ecteinascidia 
turbinate are not discussed here, since the 
producing organisms live in shallow waters 
(Koslow, 2007). Aplidium, as well as Ectein-
ascidia, belong to tunicates family, tunicates 
of the genera Aplidium can habit in different 
area of the ocean including area under 200 
meters and in cold water (Núñez-Pons et al., 
2012). 
This review likes not to be a merely clin-
ical comprehensive “list” of updated preclin-
ical/anticancer marine drugs (successful or 
not), but would like to highlight the com-
plexities of discovering and of utilizing deep 
sea-derived compounds into clinical trials. A 
great success is Ziconotide (PrialtTM Eisai 
Ltd.), a synthetic form of peptide extracted 
from the venom of predatory tropical cone 
snails Conus magus, living under 2000 me-
ters in the sea (Lewis et al., 2012). PrialtTM 
was licensed by EMA (European Medicine 
Agency] as anti-pain drug [Doc. Rif. 
EMEA/772122/2009 EMEA/H/C/551; 
http://www.ema.europa.eu/ema/index.jsp?cu
rl=pages/medicines/human/medicines/00055
1/human_med_000989.jsp&mid=WC0b01ac
058001d124].  
 
ACTINOMYCETES  
Actinomycetes are a subgroup of the ac-
tinobacteria, Gram positive bacteria with a 
high G+C ratio in their DNA. Actinomycetes 
are a prolific source of secondary metabo-
lites (SMs) that account for more than 50 % 
of antibiotics discovered to date (Manivasa-
gan et al., 2013). Marine-derived actinomy-
cetes are a “focus” in the search of novel 
SMs because of their diversity and their es-
tablished capability to produce molecules of 
pharmaceutical importance (i.e. actinomicyn) 
(Manivasagan et al., 2013). The description 
of the natural role of SMs is beyond the ob-
jective of this review; however it is im-
portant to remind that SMs are produced by 
large gene joints, including those encoding 
tailoring enzymes and mechanisms of re-
sistance and transport (Jensen, 2010). Organ-
isms produce SMs since they play important 
EXCLI Journal 2015;14:228-236 – ISSN 1611-2156 
Received: October 13, 2014, accepted: January 17, 2015, published: February 10, 2015 
 
 
230 
ecological roles such as nutrient acquisition, 
chemical communication, and defense (Jen-
sen, 2010). 
The genus Salinispora is the first obli-
gate seawater-requiring marine actinomycete 
(Mincer et al., 2005). This genus is widely 
distributed in tropical and subtropical ocean 
sediments with the species Salinispora in-
cluding S. tropica, S. arenicola, and S. 
Pacifica (Mincer et al., 2005). Salinispora 
tropica is found in tropical and subtropical 
marine sediments around the world at the 
depth of up to 1100 m (Mincer et al., 2005), 
is an aerobic, Gram-positive, non-acid-fast 
actinomycetes that form extensively 
branched substrate hyphae carrying smooth-
surfaced spores singly or in clusters. S. tro-
pica strain CNB-440 has a single circular 
chromosome composed of 5,183,331 bp, 
with no plasmids, and an average G-C con-
tent of 69.5 % (Udwary et al., 2007). S. tro-
pica produces the potent proteasome inhibi-
tor Salinosporamide-A. 
 
SALINOSPORAMIDE-A  
Salinosporamide-A [C15H20ClNO4 IU-
PAC name: (4R,5S)-4-(2-chloroethyl)-1-
((1S)-cyclohex-2-enyl(hydroxy)methyl)-5-
methyl-6-oxa-2-azabicyclo[3.2.0]heptane-
3,7-dione) or NPI-0052- or Marizomib] be-
longs to the family of salinosporamides, 
characterized by a densely functionalized -
lactam--lactone bicyclic core, that is re-
sponsible for its irreversible binding to the  
subunit of the 20S proteasome. The ubiqui-
tin-proteasome-system (UPS) is a cellular 
protease responsible for intracellular nonly-
sosomal proteolysis of aberrant folded or 
short-living proteins, complementing the 
function of lysosomes. Thus, UPS is in-
volved in signal transduction, cell cycle re-
gulation, cell differentiation and apoptosis 
(Groll and Potts, 2011). In eukaryotes, the 
26S proteasome comprises a 20S proteasome 
or core particle (CP) capped by either one or 
two 19S regulatory particles (RPs). The 20S 
proteasome core particle (CP) is the proteo-
lytically active key [https://www.google.it/ 
search?safe=active&biw=1024&bih=605&t
bm=isch&sa=1&q=proteasome+26s&oq=+
proteasom] (Marguerat et al., 2012; Kish-
Trier et al., 2012). Proteasomes may cleave 
specific amino acid residues and, according 
to these activities, they are classified as: (a) 
chymotrypsin-like, (b) trypsin-like and (c) 
caspase-like and are associated with the β5, 
β2, and β1 subunits, respectively. Dysfunc-
tion of UPS components is implicated in the 
occurrence of many human pathological dis-
orders, including cancers, cardiovascular 
diseases, viral diseases, and neurodegenera-
tive disorders (Bedford et al., 2011). Phar-
macological inhibition of UPS was originally 
considered lethal for all cell types, however 
the observation that tumor cells are more 
sensitive to proteasome inhibition than nor-
mal cells points to proteasome as a novel 
target for cancer treatment. Bortezomib (PS-
341; marketed as Velcade by Millennium 
Pharmaceuticals or Cytomib by Venus Rem-
edies) is the first proteasome inhibitor ap-
proved for the treatment of chemorefractory 
multiple myeloma (Cao et al., 2013). 
Unlike to others proteasome inhibitors 
such as Bortezomib and Carfilzomib (mar-
keted under the trade name Kyprolis by On-
yx Pharmaceuticals, Inc.) that are selective 
for the chymotrypsin-like activity of the pro-
teasome, Salinosporamide inhibits all three 
enzymatic activities of the proteasome with 
preferential activity versus chymotrypsin and 
trypsin (Chauhan et al., 2005) but also acti-
vates caspase-8 and 9 (Ruschak et al., 2011). 
The antineoplastic activity of Salinospo-
ramide is primarily on caspase-8-mediated 
signaling pathways so that it may induce 
apoptosis in cells resistant to Bortezomib. 
Salinosporamide A shows low cytotoxicity 
versus normal lymphocytes and bone mar-
row derived stem cells (Chauhan et al., 
2005). Salinosporamide (NPI-0052, market-
ed as Marizomib by Nereus Pharmaceuticals) 
is orally bioactive, inhibits tumor growth in 
mice, is well tolerated, and prolongs surviv-
al. The mechanisms of action and preclinical 
activity of Salinosporamide is reviewed in-
tensely in literature (Potts et al., 2011; Buac 
et al., 2013; Allegra et al., 2014). This com-
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pound displays potent and highly selective 
activity in The National Cancer Institute's 
(NCI) 60-cell-line panel with a mean GI50 
value (the concentration required to achieve 
50 % growth inhibition) of less than 10 nM 
and a greater than 4 log LC50 differential be-
tween resistant and susceptible cell lines. 
The greatest potency was observed against 
NCI-H226 (considered inconclusive for p53 
status) non-small cell lung cancer, SF-539 
CNS (inconclusive for p53 status) cancer, 
SK-MEL-28 melanoma (p53 mutation 
L145R), and MDA-MB-435 breast cancer 
(all with LC50 values less than 10 nM). 
NCI’s-60 cell line panel is the most exten-
sively characterized set of cells in existence 
frequently used as a screening tool for drug 
discovery [http://dtp.nci.nih.gov/branches/ 
btb/ivclsp.html]. In human clinical prelimi-
nary study Marizomib resulted generally 
well tolerated at effective doses. Common 
AEs (adverse events) include fatigue, nausea, 
vomiting, headache, dizziness, and fever. 
Dose limiting toxicities (DLT) include tran-
sient hallucinations, reversible cognitive 
changes; however peripheral neuropathy, 
thrombocytopenia and neutropenia were not 
seen. Twice weekly dosing with longer infu-
sions is active with manageable toxicity 
(Richardson et al., 2011). Table 1 shows the 
current status of clinical studies of Marizo-
mib. 
 
 
Table 1: Current status of clinical studies of Marizomib 
ClinicalTrials.gov 
Identifiera 
Study Type, 
Study Design 
Status Cancer Type Result 
NCT00667082:  
Proteasome Inhibi-
tor NPI-0052 and 
Vorinostatb 
Interventional, 
Non-randomized 
Completed Non-small Cell 
Lung Cancer, 
Pancreatic Can-
cer, Melanoma or 
Lymphoma 
The combination 
of full dose Mari-
zomib with Vori-
nostat is tolerable 
in patients with 
safety findings 
consistent with 
either drug alonec 
NCT00461045: 
Phase 1/2 Clinical 
Trial of NPI-0052, 
Single agent 
Interventional Recruiting  Relapsed or Re-
lapsed/Refractory 
Multiple Myeloma 
Not reported 
NCT02103335: 
Pomalidomided, 
Marizomib, and 
Dexamethasone 
Phase I 
Interventional 
Multicenter, 
Open-label, 
Dose-Escalation 
Recruiting Relapsed or Re-
fractory Multiple 
Myeloma 
Not reported 
NCT00629473: 
Phase 1 Clinical  
Trial of NPI-0052, 
Single agent 
Interventional, 
Non-randomized 
Completed Advanced  
Leukemia, Lym-
phoma,  
Multiple Myeloma 
Not reported 
NCT00396864: 
Phase 1 Clinical  
Trial of NPI-0052, 
Single agent 
Interventional, 
Non-randomized 
Completed Advanced Solid 
Tumor Malignan-
cies or Refractory 
Lymphoma 
Not reported 
a http://clinicaltrials.gov/ct2/results?term=Marizomib&Search=Search 
b Vorinostat (Zolinza™, Merck & Co., Inc.), a histone deacetylase inhibitor 
c Millward et al., 2012 
d Pomalidomide (CC-4047 or 3-amino-thalidomide, Pomalyst by Celgene) is a derivative of thalidomide with anti-angiogenic 
property 
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The EMA Committee for Orphan Medic-
inal Products in June 2014 adopted a positive 
opinion recommending Triphase Accelera-
tor's (a private drug development company) 
Marizomib as an orphan medicinal product 
for the treatment of multiple myeloma in the 
European Union (EU) [http://regulatory af-
fairs.pharmaceutical-business-review.com/ 
news/ema-committee-recommends-orphan-
drug-status-to-triphases-myeloma-drug-
marizomib-240614-4301119]. The EMA de-
cision follows the US Food and Drug Ad-
ministration (FDA) granting of Orphan Drug 
Status to Marizomib in March 2014 
[http://www.orphan-drugs.org/tag/Marizo-
mib/#sthash.OJtfb9BH.dpbs]. 
 
DEEP SEA DERIVED DRUGS IN  
PRECLINICAL STUDY 
Table 2 shows the current status (last five 
years) of preclinical studies of deep-sea-
derived drugs potentially useful in anticancer 
therapy. 
 
 
 
Table 2: Preclinical studies of deep-sea-derived drugs potentially useful in anticancer therapy 
Drug Source Result Reference 
Sorbicillamines A-E 
(1-5) 
Penicillium sp. 
F23-2 
Cytotoxic activity on HeLa, BEL-
7402, HEK-293, HCT-116, and 
P388 cell line 
Guo et al., 2013  
Pyrazin-2(1H) as lead 
for the development of 
ATP competitive PK 
inhibitors 
Hamacanthins 
(deep sea marine 
sponge) 
Activity against PDGFR depend-
ent cancer cells 
Pinchuk et al., 
2013  
Anthranilic acid deriv-
atives, penipacids  
A-E(1-5) 
Penicillium pane-
um SD-44. 
Inhibitory activity against human 
colon cancer RKO and Hela cell 
line  
Li et al., 2013  
Sungsanpin (1),  
15-amino-acid peptide 
Streptomyces 
species 
Inhibitory activity in invasion as-
say with the human lung cancer 
cell line A549 
Um et al., 2013  
Marthiapeptide A, tris-
thiazole-thiazoline-
containing cyclic  
peptide 
Marinactinospora 
thermotolerans 
SCSIO 00652 
Cytotoxic activity against a panel 
of human cancer cell lines  
Zhou et al., 2012 
Diketopiperazines Nocardiopsis  
alba 
Cytotoxicities against MCF-7 and 
SF-268 human cancer cell lines 
Zhang et al., 
2013  
SD118-xanthocillin X 
(1) 
Penicillium com-
mune 
Growth inhibitory effect on hu-
man hepatocellular carcinoma 
HepG2 cells. Slight apoptosis 
and autophagy via down-regulat-
ion of the MEK/ERK and up-
regulation of class III PI3K/Beclin 
1 signaling pathway 
Zhao et al., 2012 
Bis (2-ethylhexyl) 
phthalate (BEHP) 
Bacillus pumilus 
MB 40 
Anti-proliferative effect in human 
erythroleukemic K562 Apoptosis 
involving caspases pathway, be-
sides regulating mitochondrial 
enzymes. Increase in the ex-
pression of Bax mRNA concomi-
tant with a decrease in mRNA of 
Bcl-2 in K562 treated cells effec-
tive in arresting the cell cycle at a 
sub G0/G1 
Moushumi Priya 
and Jayachan-
dran, 2012  
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CANCER COMPLEXITY:  
HOW SYSTEMS BIOLOGY EMBRAC-
ING SYSTEMS MEDICINE MAY HELP 
TO DEVELOP BETTER ANTICANCER 
THERAPEUTIC STRATEGIES 
Cancer is a complex disease representa-
ble in the form of a high nonlinear system 
characterized by continuous changes in dif-
ferent signaling pathways and molecular 
networks regulated by complex behaviors 
such as self-organization, dissipative struc-
tures, biological clock, fractals and chaos. 
Hundreds to thousands genetic and epigenet-
ic alterations occur inside a cancer cell re-
sulting in expression of aberrant or abnormal 
proteins that may lead to uncontrolled tran-
scriptional and translational regulation. 
Complex interactions with microenviron-
ment are also involved (Du and Elemento, 
2014; Li and Mansmann, 2014; Masoudi-
Nejad and Wang, 2015; Werner et al., 2014; 
Tang and Aittokallio, 2014). Scientific pro-
gress allowed the identification of various 
hallmarks underlying the cancer phenotype 
(Figure 1) (Hanahan and Weinberg, 2000, 
2011), although more hallmarks remain to be 
elucidated.  
 
Figure 1: Hallmarks of cancer. This illustration 
shows different hallmark capabilities that were 
originally proposed in 2000 by Hanahan and 
Weinberg and then modified in 2010 by the same 
authors. Figure is adapted by  
http://www.istockphoto.com/vector/cycle-
stickman-2-0-10708124?st=0e7e21f 
 
 
It is well known that “complex systems 
relay on the use of mathematical tools based 
on networks or graphs, where the individual 
parts translate to nodes and the interactions 
translate to edges or links” (Saetzler et al., 
2011). A biological network, that is consid-
ered scale-free, may be mathematically re-
presented as a matrix or graphically as a 
network diagram composed by graph points 
or nodes, that represent genes or proteins, 
connected by lines representing interactions 
(edges). As a result, the centrality of a node 
may be easily measured using computational 
methods (Saetzler et al., 2011) and the 
strength or confidence of the edge may be 
weighted. The “constituents” of the structure 
may be simple as proteins (nodes) or pro-
tein–protein interactions (as edges) or com-
plicated as drugs and target proteins (differ-
ently shaped nodes) or drug–target bindings 
(edges) (Chen et al., 2013). According to the 
principle of “network medicine” each signal-
ing network is an extremely dynamic entity. 
Dynamic cellular networks have a finite 
number of states that may be represented as 
landscapes. This dynamic nature is the criti-
cal property of cancer signaling network that 
may be perturbed by mutations, that, at a 
systems-level, ultimately may impair the 
normal cell physiology and allow cells to 
acquire key cancer hallmarks such as uncon-
trolled/sustained cell-proliferation and apop-
tosis escape (Hanahan and Weinberg, 2000, 
2011). Currently, the knowledge of these 
molecular interaction networks is a key chal-
lenge to achieve a deeper understanding of 
cancer biology and to identify novel drug 
targets. The knowledge of specific biochem-
ical pathways, as well as the knowledge of 
their environmental modifications (i.e. oxi-
dized posttranslational modifications of pro-
teins), integrated by several “omics” data 
(i.e. genomics, transcriptomics, proteomics, 
metabolomics) may have great power to 
identify relevant interactions that in turn may 
allow to determine drug targets (or combina-
tion of) yielding the optimal benefit with 
minimal adverse consequences. A simple 
consequence of network perspective is the 
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change of the concept of target entity from a 
single protein to a whole molecular pathway 
and/or cellular network. Salinosporamide A 
is an inhibitor of UPS (Einsele, 2014). Pro-
teasome, constituting up to 5 % of the total 
protein content, represents the second-most 
abundant protein complexes (Marguerat et 
al., 2012). It is a collection of complexes 
based on the 20S proteasome core particle 
(20S CP). 20S is a complex formed by 28 
subunits housing proteolytic sites inside its 
hollow interior (Kish-Trier et al., 2012). Pro-
teasomes are found in archaea, some eubac-
teria, and in eukaryotes. Proteasome is con-
sidered as one of the most important cellular 
protein degradation machinery. It functions 
as a “gatekeeper” controlling the execution 
of protein degradation thus playing a crucial 
role in the ubiquitin-proteasome pathway 
(UPP). Proteasome works catalyzing the hy-
drolysis of amide bonds adjacent to a variety 
of amino acids through chymotrypsin-like, 
trypsin-like and post-glutamyl peptide hy-
drolyzing activity. UPS degrades around 80-
90 % of the total intracellular proteins aber-
rantly folded or typically short-lived whereas 
the remaining 10-20 % is degraded by the 
lysosomes (Settembre and Ballabio, 2014). 
UPS is a promising significant therapeutic 
target since it is involved in many cellular 
processes and pathways, such as proteins 
turnover, quality control of proteins, tran-
scription, cell signaling, cell cycle, apopto-
sis, inflammation, immune response includ-
ing antigen presentation, and development. 
Indeed, malfunction of UPS components (i.e. 
lack of proper control over UPS) is involved 
in different human diseases and is attributed 
to both cancer and to neurodegenerative dis-
orders, yet in different context and direction 
(Jara et al., 2013). The UPS regulates the 
turnover of p53 and p27Kip1 as well as the 
activation of nuclear factor kappa B (NF-B) 
signaling, thereby supporting cancer cell 
survival and proliferation (Jara et al., 2013). 
Salinosporamide A potentiates the apoptosis 
induced by tumor necrosis factor alpha 
(TNF), Bortezomib, and thalidomide down-
regulating the gene products that mediate 
cell proliferation such as cyclin D1, cyclo-
oxygenase-2 (COX-2), and c-Myc, cell sur-
vival factors such as Bcl-2, Bcl-xL, cFLIP, 
TRAF1, IAP1, IAP2, and survivin, invasion 
such as matrix metalloproteinase-9 (MMP-9) 
and ICAM-1, as well as angiogenesis (vascu-
lar endothelial growth factor [VEGF]). 
Salinosporamide A also suppressed TNF-
induced tumor cell invasion and receptor ac-
tivator of NF-B ligand (RANKL)-induced 
osteoclastogenesis and suppresses both con-
stitutive and inducible NF-B activation 
(Anh et al., 2007). 
 
CONCLUSIONS 
The majority of “targeted-drugs” used 
now in cancer therapy has the limitation to 
affect a single gene or a single protein, or in 
some cases multiple kinases. This “reduc-
tionist” approach may lead to wrong deci-
sions as shown, for an example, by Janes et 
al. (2005) who found that, according on the 
state of the signaling network, the protein 
Jun N-terminal kinase may have either a pro- 
or an antiapoptotic effect. The “integrated 
network modeling” suggests that a drug can-
didate shall take into account the ability of 
the system itself to adapt to perturbation 
(e.g., drug resistance) proposing a new ap-
proach called “magic shotguns” to find a few 
special molecule that broadly disrupts the 
whole diseases process. Deep-sea-derived 
compounds, as exemplified by Salinospo-
ramide, fit well into this concept. 
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